Veronica Wu, founder of First Bight Ventures, joins the Houston Innovators Podcast to outline Houston's opportunities in synthetic biology and biomanufacturing. Photo courtesy

Houston has all the ingredients to be a successful synthetic biology hub, says Veronica Wu. She believes so strongly in this that she relocated to Houston from Silicon Valley just over a year ago to start a venture capital firm dedicated to the field. Since then, she's doubled down on her passion for Houston leading in biotech — especially when it comes to one uniquely Houston opportunity: biomanufacturing.

While Houston's health care innovation scene is actively deploying synthetic biology applications, Wu points to Houston-based Solugen, a plant-based chemical producer, as an example of what Houston has to offer at-scale industrial biomanufacturing. Houston has the workforce and the physical space available for more of these types of biomanufacturing plants, which have a huge potential to move the needle on reducing carbon emissions.

"This is really fundamental technology that's going to change the paradigm and whole dialogue of how we are making a significant impact in reducing a carbon footprint and improving sustainability," says Wu, founder and managing partner of First Bight Ventures, on the Houston Innovators Podcast.

Several aspects — government funding, corporate interest, advances in technology — have converged to make it an ideal time for synthetic biology innovators and investors, Wu explains on the show, and she has an idea of what Houston needs to secure its spot as a leader in the space: The BioWell.

First introduced at a Houston Tech Rodeo event at the Texas Medical Center's Innovation Factory, The BioWell is a public-private partnership that aims to provide access to pilot and lab space, mentorship and programming, and more support that biomanufacturing innovators critically need.

"The way we envision The BioWell is it will provide a holistic, curated support for startups to be able to get across the Valley of Death," Wu says, explaining that startups transitioning from research and development into commercialization need extra support. The BioWell will provide that, as well as allow more engagement from corporations, investors, and other players.

Now that her plans for The BioWell have been announced, Wu is looking for those who want to be a part of it.

She shares more about her mission and what's next for First Bight Ventures on the podcast. Listen to the interview below — or wherever you stream your podcasts — and subscribe for weekly episodes.

Finding funding is tough and might get you in the mother of all holes — the Valley of Death. Miguel Tovar/University of Houston

7 ways to escape the Valley of Death, according to University of Houston research

Houston Voices

To walk through the valley of death means that death and misery are low points (valleys) in the human experience through which we all must inevitably walk and experience.

Although not as morbid, in the world of startup businesses, the valley of death is still grim. It is a low point in your startup's life where your business suffers and all seems lost. Specifically, it describes how hard it is to cover negative cash flow while you wait for your startup to start generating revenue from actual consumers. Sadly, only 10 percent of startups will survive the valley of death after the first three years, according to a Gompers and Lerner analysis.

"Our startup overcame the valley of death by making believers out of investors. Often, you have ideas that are worthwhile, but you have to find investors who also believe that," says Jason Eriksen, Ph.D., associate professor of pharmacology and chair and co-founder of Alzeca Biosciences.

Alzeca develops advanced imaging technology that helps physicians detect Alzheimer's at a much earlier stage than ever before. Alzeca is one of 28 groundbreaking and innovative startups changing the world at UH's Technology Bridge.

"Initially, our investors rejected us because they were disappointed that we couldn't cure Alzheimer's, and that we could merely stage it. That sent us spiraling into the valley of death. We overcame that by making other investors believers. We made them believe in our technology for detecting the disease early and that it would be life-changing for millions of sufferers," Eriksen says.

Here are another seven ways to dig yourself out of, not just a hole, but the mother of all holes: the valley of death.

1. Gather resources.

Planning your business is a good way to minimize risk. Such preparation involves determining how much money you will need to get to the revenue generation stage, and how much money you will need to cover costs in the likely event you fall into a financial hole. The more resources you've accumulated beforehand, the more padding you'll have if you fall on your face.

2. Don't quit your day job.

Keep your day-to-day job to keep money coming in and your personal finances covered. Use your weeknights and weekends to put in work on your company while you wait to generate revenue. You'll be making money while you wait for money. This way might take longer, but with proper planning, you can ensure that your lights will stay on while your startup struggles to bring in revenue while spiraling in the valley of death.

3. Find funding from friends and family.

"Angel investors and venture capitalists will feel a lot better about investing if they see you already have money at stake," Eriksen says.

That pre-investor money usually comes from friends and family. There is some weight to the idea that you should never mix business with family, but there are exceptions.

You're more likely to secure funding from friends and family if you show them you have a more-than-solid business plan. Your loved ones will want to see figures and metrics that have tracked what your business has done or what it is projected to do. They will also want to see that you are an expert in your business. It would also help to show them a payment plan where you outline when and how you will pay their money back.

Once you have friends and family funding secured, you're a lot more likely to acquire more funding from investors, and the long, hard road out of the valley of death begins.

4. Call for crowdfunding.

One smart way to jet pack out of the valley of death is to launch a crowdfunding campaign. If you know your tech, service, or product is a game changer, crowdfunding will put that to the test. This is where you'll obtain funding from everyday people who like what you have to offer enough to put all their faith in it in the form of dollars and cents.

5. Enter competitions and apply for grants.

Enter as many competitions as you can.

"Because of the government's recent surge in focus on tech-based and energy-based startups, there are now more startup competitions available in major VC (venture capitalist) geographic hotspots like San Francisco, Boston, New York, LA, and San Jose," Eriksen says.

While those cities are the startup hotspots, their activity reflects the current market for startups all over the country. Thankfully, that activity is at an all-time high, so you can rest assured that startup competitions are abundant in your own city, too.

This is your chance to show the world your hoverboard and attain funding you don't have to pay back, all without even relinquishing any equity. These competitions are, get this, competitive, so it would wise to register as early as you can.

6. Consider joint venture.

There might be a company out there that sees your product or services as congruent to their own business. Reach out to them and try to convince them that a joint venture would behoove both companies. This approach is not uncommon, and companies have been known to advance funding early on with the expectation that you'll reimburse them once your revenue starts rolling in.

7. Borrow if need be. 

Somewhere out there is a loan with your name on it. Wallowing in the valley of death can really leave a business owner feeling desperate and alone in the world. So desperate, that is, that they might mess around and apply for a loan. This alternative is the nuclear option. A last resort. It's only a viable approach if you're willing to put your home or other big assets on the line as collateral.

Typically, banks will only approve loans to startups that are cash-flow positive. So maybe this option is best if you've succeeded with a few of the aforementioned approaches so much that they helped your company start generating revenue. Once you've reached that point, that's the prime time to apply for a loan or line of credit.

"The phrase 'valley of death' is appropriate because it is a death sentence for the vast majority of startups," warns Eriksen.

That doesn't mean you go down without a fight.

When Buster Douglas fought Mike Tyson, every fan, expert, and sportswriter counted him out. For the entire fight, they were right. His defeat was inevitable. Then the tenth round happened.

Not only did he not go down without a fight, he won the bout. He beat the champ, and the odds. If you want your best chance at beating the odds, you do everything you can. You fight. Loans, competitions, crowdfunding, joint ventures; whatever it takes.

"The valley of death is only a death sentence if you allow it to be."

------

This article originally appeared on the University of Houston's The Big Idea.

The author, Rene Cantu, is the writer and editor at UH Division of Research.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston startup debuts bio-based 'leather' fashion collection in Milan

sustainable fashion

Earlier this month, Houston-based Rheom Materials and India’s conscious design studio Econock unveiled a collaborative capsule collection that signaled more than just a product launch.

Hosted at Lineapelle—long considered the global epicenter of the world's premier leather supply chain—in the vaulted exhibition halls of Rho-Fiera Milano, the collection centered around Rheom’s 91 percent bio-based leather alternative, Shorai.

It was a bold move, one that shifted sustainability from a concept discussed in panel sessions to garments that buyers could touch and wear.

The collection featured a bomber-style jacket, an asymmetrical skirt and a suite of accessories—all fabricated from Shorai.

The standout piece, a sculptural jacket featuring a funnel neck and dual-zip closure, was designed for movement, challenging assumptions about performance limitations in bio-based materials. The design of the asymmetrical skirt was drawn from Indian armored warrior traditions, according to Rheom, with biodegradable corozo fasteners.

Built as a modular wardrobe rather than isolated pieces, the collection reflects a shared belief between Rheom and Econock in designing objects that adapt to daily life, according to the companies.

The collection was born out of a new partnership between Rheom and Econock, focused on bringing biobased materials to the market. According to Rheom, the partnership solves a problem that has stalled the adoption of many next-gen textiles: supply chain friction.

While Rheom focuses on engineering scalable bio-based materials, New Delhi-based Econock brings the complementary design and manufacturing ecosystem that integrates artisans, circular materials and production expertise to translate the innovative material into finished goods.

"This partnership removes one of the biggest barriers brands face when adopting next-generation materials,” Megan Beck, Rheom’s director of product, shared in a news release. “By reducing friction across the supply chain, Rheom can connect brands directly with manufacturers who already know how to work with Shorai, making the transition to more sustainable materials far more accessible.”

Sanyam Kapur, advisor of growth and impact at Econock, added: “Our partnership with Rheom Materials represents the benchmark of responsible design where next-gen materials meet craft, creativity, and real-world scalability.”

Rheom, formerly known as Bucha Bio, has developed Shorai, a sustainable leather alternative that can be used for apparel, accessories, car interiors and more; and Benree, an alternative to plastic without the carbon footprint. In 2025, Rheom was a finalist for Startup of the Year in the Houston Innovation Awards.

Shorai is already used by fashion lines like Wuxly and LuckyNelly, according to Rheom. The company scaled production of the sugar-based material last year and says it is now produced in rolls that brands can take to market with the right manufacturer.

Houston startup debuts leather alternative fashion collection in Milan

Houston clean energy co. secures $100M to deploy tech on global scale

Going Global

Houston-based Utility Global has raised $100 million in an ongoing Series D round to globally deploy its decarbonization technology at an industrial scale.

The round was led by Ara Partners and APG Asset, according to a news release. Utility plans to use the funding to expand manufacturing, grow its teams and support its commercial developments and partnerships.

“This financing marks a critical step in Utility’s transition from a proven technology to full-scale global commercial execution,” Parker Meeks, CEO and president of Utility Global, said in the release. “Industrial customers are no longer looking for pilots or promises; they need deployable solutions that work within existing assets and deliver true economic industrial decarbonization today that is operationally reliable and highly scalable. Utility’s technology produces both economic clean hydrogen and capture-ready CO2 streams, and this capital enables us to scale and deploy that impact globally with speed, discipline, and rigor.”

Utility Global's H2Gen technology produces low-cost, clean hydrogen from water and industrial off-gases without requiring electricity. It's designed to integrate into existing industrial infrastructure in hard-to-abate assets in the steel, refining, petrochemical, chemical, low-carbon fuels, and upstream oil and gas sectors.

“Utility is tackling one of the most difficult challenges in the energy transition: decarbonizing hard‑to‑abate industrial sectors,” Cory Steffek, partner at Ara Partners and Utility Global board chair, said in the release. “What sets Utility apart is its ability to compete head‑to‑head with conventional fossil‑based solutions on cost and reliability, even as it materially reduces emissions. With this new funding, Utility is well-positioned for its next chapter of commercial growth while maintaining the technical excellence and capital discipline that have defined its development to date.”

Utility Global reached several major milestones in 2025. After closing a $53 million Series C, the company agreed to develop at least one decarbonization facility at an ArcelorMittal steel plant in Brazil. It also signed a strategic partnership with California-based Kyocera International Inc. to scale global manufacturing of its H2Gen electrochemical cells.

The company also partnered with Maas Energy Works, another California company, to develop a commercial project integrating Maas’ dairy biogas systems with H2Gen to produce economical, clean hydrogen.

"These projects were never intended to stand alone. They anchor a deep and growing pipeline of commercial projects now in development globally across steel, refining, chemicals, biogas and other hard-to-abate sectors worldwide, Meeks shared in a 2025 year-in-review note. He added that 2026 would be a year of "focused acceleration to scale."

---

This article originally appeared on EnergyCapitalHTX.com.

Houston Methodist awarded $4M grant to recruit head of Neal Cancer Center

new hire

Armed with a $4 million state grant, the Houston Methodist Academic Institute has recruited a renowned expert in ovarian and endometrial cancer research to lead the Dr. Mary and Ron Neal Cancer Center.

The grant, provided by the Cancer Prevention and Research Institute of Texas, enabled the institute to lure Dr. Daniela Matei away from Northwestern University’s Feinberg School of Medicine in Chicago. There, she is the Diana Princess of Wales Professor in Cancer Research and chief of the Division of Reproductive Science in Medicine.

Matei will succeed Dr. Jenny Chang, who was hired last year to run the Houston Methodist Academic Institute.

At the Neal Cancer Center, located in the Texas Medical Center complex, oncologists work on innovations in cancer research, treatment, and technology. The center opened in 2021 after the Neals donated $25 million to expand Houston Methodist’s cancer research capabilities. It handles about 7,000 new cases each year involving more than two dozen types of cancer.

U.S. News & World Report puts Houston Methodist Hospital at No. 19 among the country’s best hospitals for cancer care, two spots below Chicago’s Northwestern Memorial Hospital. The University of Texas MD Anderson Cancer Center in Houston sits at No. 1 on the list.

Matei’s research related to ovarian and endometrial cancer holds the potential to benefit tens of thousands of American women. The American Cancer Society estimates:

  • 21,010 women in the U.S. will be diagnosed with ovarian cancer, and 12,450 women will die from it.
  • 68,270 women in the U.S. will be diagnosed with endometrial cancer, and 14,450 women will die from it.

Matei is leaving Northwestern in the wake of widespread cuts in federal funding for medical research. The National Institutes of Health (NIH) has canceled or frozen tens of millions of dollars in grants for Northwestern, the Wall Street Journal reports, and the university has been plugging the gaps with its own money.

“The university is totally keeping us on life support,” Matei told the newspaper last year. “The big question is for how long they can do this.”

According to the Wall Street Journal, Matei’s $5 million NIH grant supporting 69 cancer trials has been caught up in the federal funding chaos, so Northwestern stepped in to cover trial expenses such as nurses’ salaries and diagnostic procedures.

Trial participants include some patients with rare, incurable tumors who are undergoing experimental treatments aligned with the genetics of their condition, the newspaper says.

“It’s certainly a life-and-death situation for cancer patients on these trials,” Matei said in 2025.

Matei is among the beneficiaries of more than $15 million in grants approved February 18 by CPRIT’s board. The grants went toward recruiting five cancer researchers to institutions in Texas.

One of those grants, totaling $1.5 million, went to the University of Houston to recruit Akash Gupta, a research scientist at MIT’s Koch Institute for Integrative Cancer Research. The remaining grants went to recruit scientists to The University of Texas at Dallas and The University of Texas Southwestern Medical Center.